|
|
|
| Effect of Jiedu Huayu Ⅱ Decoction on the expression of Th17 and Th1 in peripheral blood of patients with HBV related acute liver failure and its clinical efficacy |
| SHI Qinglan MAO Dewen CHEN Yueqiao LYU Jianlin |
| The First Ward of Department of Hepatopathy, the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Guangxi Zhuang Autonomous Region, Nanning 530023, China |
|
|
|
Abstract Objective To investigate the effects of Jiedu Huayu Ⅱ Decoction on the expression of Th17 and Th1 in peripheral blood of patients with HBV related acute liver failure and its clinical efficacy. Methods From February 2013 to March 2016, 118 patients with HBV related acute liver failure treated in the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Rukang Hospital affiliated to Guangxi University of Traditional Chinese Medicine and Tiandong Hospital of Traditional Chinese Medicine were divided into control group and observation group according to random number table, with 59 cases in each group. The control group was treated with western medicine dialectical therapy, and the observation group were treated by Jiedu Huayu Ⅱ Decoction and Western medicine dialectical therapy. After 8 weeks of treatment, the clinical efficacy, biochemical indexes and the expression levels of Th17 and Th1 in peripheral blood of two groups were evaluated. Results The total effective rate of the observation group was higher than that of the control group (P < 0.05). After treatment, the AST, ALT and TBiL of the observation group were lower than those of the control group, and PTA was higher than that of the control group, with statistically significant difference (P < 0.05). After treatment, the proportion of Th17 and Th1 cell in the observation group was lower than that of the control group, and the Th1/Th17 value of the observation group was higher than that of the control group, with statistically significant difference (P < 0.05). Conclusion Jiedu Huayu Ⅱ Decoction can effectively improve the liver function of patients with HBV related acute liver failure, decline the Th17 and Th1 expression, which has high clinical value.
|
|
|
|
|
|
[1] 雷青，孟忠吉.慢加急性肝衰竭的研究进展[J].中国医药导报，2016，13（14）：45-48.
[2] 田小利，彭颖，吴松林，等.肝衰竭分期联合MELD评分对肝衰竭短期预后判断的研究[J].重庆医学，2017，46（8）：1079-1081.
[3] 吴蓓，朱丽，段萌，等.双重血浆分子吸附系统治疗乙肝慢加急肝衰竭患者疗效及其对T淋巴细胞亚型的影响[J].疑难病杂志，2016，15（6）：584-587，591.
[4] 田沂，龚国忠.乙型肝炎病毒再激活致肝衰竭病例及其机制分析[J].中华肝脏病杂志，2014，22（4）：272-276.
[5] 刘晓桐.中西医结合治疗乙型肝炎病毒相关慢加急性肝衰竭的临床效果分析[J].中外医学研究，2017，15（21）：7-8.
[6] Polson J，Lee WM. American Association for the Study of Liver Disease. AASLD position paper：the management of acute liver failure [J]. Hepatology，2005，41（5）：1179-1197.
[7] 国家中医药管理局.中药新药临床研究指导原则[S].北京：中国医药科技出版，2002.
[8] 中华医学会感染病学分会肝衰竭与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南（2012年版）[J].中华肝脏病杂志，2013，21（3）：177-183.
[9] 易伟愿，邱华，张荣臻.中西医结合治疗重型肝炎优势分析[J].内蒙古中医药，2012，31（16）：26-27.
[10] 邹美银，章幼奕，周辉娟，等.血清Th17、IL-17与HBV相关性慢加亚急性、慢性肝衰竭的相关性[J].江苏医药，2013，（13）：1520-1524.
[11] 毛德文，邱华，余晶，等.解毒化瘀Ⅱ方对实验性暴发性肝衰竭大鼠的保护作用[J].中医研究，2006，19（12）：13-15.
[12] 陆小华，马骁，王建，等.赤芍的化学成分和药理作用研究进展[J].中草药，2015，46（4）：595-602.
[13] 华圆，冯健，李范珠.茵陈蒿汤利胆退黄物质基础的研究进展[J].中华中医药学刊，2011，29（7）：1520-1521.
[14] 王安庆.茵陈的现代研究进展[J].光明中医，2014，29（10）：2207-2208.
[15] 侯山岭.中药白花蛇舌草化学成分及药理活性研究进展[J].中医临床研究，2018，10（6）：140-141.
[16] 毛德文，邱华，胡振斌，等.解毒化瘀Ⅱ方对暴发性肝衰竭大鼠肝线粒体内Ca2+稳态的影响[J].中国临床康复，2006，10（31）：70-72.
[17] 邱华，毛德文，农朝赞，等.解毒化瘀Ⅱ方对暴发性肝衰竭大鼠肝线粒体Bcl-2及Cytochrome C表达的影响[J].中国康复理论与实践，2007，13（3）：51-53.
[18] 毛德文，邱华，马银瑶，等.解毒化瘀Ⅱ方对肝衰竭大鼠肝线粒体的保护作用[J].中华中医药学刊，2007，25（5）：18-20.
[19] 范秋霞，王春美，盛光耀.Th17细胞和白细胞介素－17在儿童过敏性紫癜发病中作用[J].中华实用诊断与治疗杂志， 2010，24（11）：1089-1090.
[20] Liu X，Zhao X， Wang X，et al. Photochemically inactivated hepatitis B virus upregulation of Th1-type cytokines [J]. Photochem Photobiol，2012，88（5）：1287-1292. |
|
|
|
